AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9585797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7635364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) with 0.5 ml of inseminate
Number of subjects: 60
Study 7635364 — intervention group
Group type: COMPARATOR
Intervention: Fallopian sperm perfusion (FSP) with 4 ml of inseminate
Number of subjects: 60
Study 2712130 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol
Number of subjects: 46
Study 2712130 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 46
Study 408844 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg
Number of subjects: 0
Study 408844 — intervention group
Group type: EXPERIMENTAL
Intervention: l-amphetamine 10 mg
Number of subjects: 0
Study 408844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11161899 — intervention group
Group type: EXPERIMENTAL
Intervention: ESBL-KP
Number of subjects: 92
Study 11161899 — intervention group
Group type: COMPARATOR
Intervention: non-ESBL-KP
Number of subjects: 92
Study 11161899 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbapenems
Number of subjects: 92
Study 31013226 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg daily for up to 5 days before surgery)
Number of subjects: 572
Study 31013226 — intervention group
Group type: COMPARATOR
Intervention: Medication-free group (no aspirin)
Number of subjects: 572
Study 30158152 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor (15 mg, given twice daily for 4 days)
Number of subjects: 0
Study 27623732 — intervention group
Group type: EXPERIMENTAL
Intervention: All-inside arthroscopic MBO
Number of subjects: 48
Study 27623732 — intervention group
Group type: COMPARATOR
Intervention: Open MBO
Number of subjects: 48
Study 24569916 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant cisplatin‐based combination chemotherapy
Number of subjects: 0
Study 24569916 — intervention group
Group type: COMPARATOR
Intervention: Cystectomy alone or surgery followed by adjuvant chemotherapy
Number of subjects: 0
Study 23230999 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxylamine hydrogen succinate 25 mg under fed conditions
Number of subjects: 24
Study 23230999 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxylamine hydrogen succinate 25 mg under fasting conditions
Number of subjects: 24
Study 20500493 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate everolimus (IE)
Number of subjects: 139
Study 20500493 — intervention group
Group type: COMPARATOR
Intervention: Delayed everolimus (DE)
Number of subjects: 139
Study 17610347 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin-based regimen
Number of subjects: 2
Study 17610347 — intervention group
Group type: COMPARATOR
Intervention: UFH/PPC-based regimen
Number of subjects: 2
Study 15850130 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex Demodulation (CDM)
Number of subjects: 0
Study 15850130 — intervention group
Group type: COMPARATOR
Intervention: Power Spectral Analysis (PSA)
Number of subjects: 0
Study 12850621 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrosurgical bipolar vessel sealer
Number of subjects: 60
Study 12850621 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 60
Study 10568115 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (Duraflo II, n = 20)
Number of subjects: 40
Study 8911631 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG infusions (200-250 mg/kg) every 3 weeks during the first 8 months of pregnancy
Number of subjects: 35
Study 1868270 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic hPTH (1‐38) for the first 14 days of a 100 day cycle, followed by no other therapy (Group 1)
Number of subjects: 2
Study 1868270 — intervention group
Group type: COMPARATOR
Intervention: Synthetic hPTH (1‐38) for the first 14 days of a 100 day cycle followed by salmon calcitonin at an average dose of 79 units per day for a 56 day depressor period (Group 2)
Number of subjects: 2
Study 7040782 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion
Number of subjects: 50
Study 7040782 — intervention group
Group type: COMPARATOR
Intervention: Nondopamine group (Control)
Number of subjects: 50
Study 31711671 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin administered intraamniotically or intrafetally prior to second-trimester surgical abortion
Number of subjects: 0
Study 31711671 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 0
Study 29863842 — intervention group
Group type: EXPERIMENTAL
Intervention: Onion-ring-like g-C3N4
Number of subjects: 0
Study 29863842 — intervention group
Group type: COMPARATOR
Intervention: Bulk g-C3N4
Number of subjects: 0
Study 26360921 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous flow limb hypothermia at coolant temperatures between 25 °C and 20 °C for three hours
Number of subjects: 15
Study 26360921 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous flow limb hypothermia at coolant temperatures as low as 22 °C
Number of subjects: 15
Study 24047244 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot Massage (FM)
Number of subjects: 53
Study 24047244 — intervention group
Group type: COMPARATOR
Intervention: Control Activity (Quiet Presence, QP)
Number of subjects: 53
Study 23534333 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE treatment (n = 12)
Number of subjects: 23
Study 23534333 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls (n = 11)
Number of subjects: 23
Study 21034619 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy
Number of subjects: 85
Study 21034619 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study 17437965 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinitapride (CTP; 1 mg t.i.d.) + ketoconazole (KET; 200 mg b.i.d.)
Number of subjects: 16
Study 17437965 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinitapride (CTP; 1 mg t.i.d.) + placebo (PL)
Number of subjects: 16
Study 17437965 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) + ketoconazole (KET; 200 mg b.i.d.)
Number of subjects: 16
Study 17437965 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) + placebo (PL)
Number of subjects: 16
Study 17902397 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in the meaning of the symbols
Number of subjects: 2
Study 17902397 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 2
Study 12196473 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg/day)
Number of subjects: 266
Study 12196473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study 10461824 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg
Number of subjects: 0
Study 10461824 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 200 mg
Number of subjects: 0
Study 7835575 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine (3 g/day)
Number of subjects: 87
Study 7835575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 2151276 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex plus flutamide
Number of subjects: 0
Study 2151276 — intervention group
Group type: COMPARATOR
Intervention: Zoladex plus placebo
Number of subjects: 0
Study 385260 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 28
Study 385260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31818058 — intervention group
Group type: EXPERIMENTAL
Intervention: Music (M)
Number of subjects: 15
Study 31818058 — intervention group
Group type: COMPARATOR
Intervention: No Music (NM)
Number of subjects: 15
Study 31129719 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 38
Study 31129719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 28124127 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise (END: 30 min cycling, 70% VO2peak)
Number of subjects: 9
Study 28124127 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (REX: 4 × 10 leg press repetitions, 70% 1-RM)
Number of subjects: 9
Study 28124127 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity cycling with blood-flow restriction (BFR: 15 min, 40% VO2peak)
Number of subjects: 9
Study 25919835 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase to 30 mg/d of mirtazapine (increase(30) group)
Number of subjects: 44
Study 25919835 — intervention group
Group type: COMPARATOR
Intervention: Maintain at 15 mg/d of mirtazapine (stay(15) group)
Number of subjects: 44
Study 25919835 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase to 45 mg/d of mirtazapine (increase(45) group)
Number of subjects: 44
Study 25919835 — intervention group
Group type: COMPARATOR
Intervention: Maintain at 30 mg/d of mirtazapine (stay(30) group)
Number of subjects: 44
Study 24919430 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based GA-coping computer game
Number of subjects: 210
Study 24919430 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 210
Study 24919430 — intervention group
Group type: COMPARATOR
Intervention: Non-medical game
Number of subjects: 210
Study 22961272 — intervention group
Group type: EXPERIMENTAL
Intervention: Local injections of rhGH
Number of subjects: 12
Study 22961272 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study 19773751 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery followed by adjuvant chemotherapy
Number of subjects: 409
Study 19773751 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 409
Study 19773751 — intervention group
Group type: EXPERIMENTAL
Intervention: High EZH2 expression
Number of subjects: 409
Study 19773751 — intervention group
Group type: EXPERIMENTAL
Intervention: High proliferation (>or=40%)
Number of subjects: 409
Study 19773751 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomisation group (high proliferation)
Number of subjects: 409
Study 19773751 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III
Number of subjects: 409
Study 19773751 — intervention group
Group type: EXPERIMENTAL
Intervention: High histological grade
Number of subjects: 409
Study 19773751 — intervention group
Group type: EXPERIMENTAL
Intervention: High proliferation
Number of subjects: 409
Study 17706059 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced osmolarity oral rehydration salts (ROORS)
Number of subjects: 125
Study 17706059 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration salts II (ORS II)
Number of subjects: 125
Study 15045139 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV-C (1 g/kg/day for 2 days)
Number of subjects: 97
Study 15045139 — intervention group
Group type: COMPARATOR
Intervention: IGIV-S/D (1 g/kg/day for 2 days)
Number of subjects: 97
Study 15045139 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV-C
Number of subjects: 97
Study 15045139 — intervention group
Group type: COMPARATOR
Intervention: IGIV-S/D
Number of subjects: 97
Study 11579248 — intervention group
Group type: EXPERIMENTAL
Intervention: bDNA assay for HIV-1 RNA
Number of subjects: 106
Study 10378439 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive automation system using EEG engagement indices (beta/(alpha + theta), beta/alpha, or 1/alpha)
Number of subjects: 0
Study 10378439 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive automation system using absolute levels of engagement
Number of subjects: 0
Study 10378439 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative feedback condition
Number of subjects: 0
Study 10378439 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta/(alpha + theta) index
Number of subjects: 0
Study 7493311 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-alpha 3 MU thrice weekly (group A)
Number of subjects: 112
Study 7493311 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-alpha 6 MU thrice weekly (group B)
Number of subjects: 112
Study 7493311 — intervention group
Group type: EXPERIMENTAL
Intervention: L-IFN 3 MU thrice weekly (group C)
Number of subjects: 112
Study 7493311 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group D)
Number of subjects: 112
Study 2148877 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-operative chemotherapy
Number of subjects: 53
Study 2148877 — intervention group
Group type: COMPARATOR
Intervention: Control (no peri-operative chemotherapy)
Number of subjects: 53
Study 6995640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 232
Study 6995640 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 232
Study 31852118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortex Eucommiae (CE) extract for 12 weeks
Number of subjects: 100
Study 31852118 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 100
Study 28961845 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg apatorsen
Number of subjects: 183
Study 28961845 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg apatorsen
Number of subjects: 183
Study 28961845 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg apatorsen (poor prognostic features)
Number of subjects: 183
Study 28961845 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg apatorsen (lower sHsp27 levels)
Number of subjects: 183
Study 28961845 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg apatorsen (lower sHsp27 levels)
Number of subjects: 183
Study 28961845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 25742559 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic wave therapy (AWT)
Number of subjects: 15
Study 24444704 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal retraining (biofeedback)
Number of subjects: 157
Study 24444704 — intervention group
Group type: COMPARATOR
Intervention: Standard conservative treatment (control)
Number of subjects: 157
Study 22458860 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 300
Study 22458860 — intervention group
Group type: COMPARATOR
Intervention: Amodiaquine (AQ)
Number of subjects: 300
Study 19829175 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle changes, pharmacotherapy, and psychologic interventions
Number of subjects: 0
Study 17459081 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 81
Study 15333884 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 second anti‐smoking advertisement shown before the movie in week 2
Number of subjects: 2038
Study 15333884 — intervention group
Group type: COMPARATOR
Intervention: Control group surveyed during week 1
Number of subjects: 2038
Study 11231437 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 320
Study 11231437 — intervention group
Group type: COMPARATOR
Intervention: eptifibatide
Number of subjects: 320
Study 11323363 — intervention group
Group type: EXPERIMENTAL
Intervention: Small Ketamine (0.25 mg/kg)
Number of subjects: 85
Study 11323363 — intervention group
Group type: EXPERIMENTAL
Intervention: Large Ketamine (1.0 mg/kg)
Number of subjects: 85
Study 11323363 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 85
Study 9217714 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide, 600 mg twice daily
Number of subjects: 22
Study 9217714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9217714 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 22
Study 8394749 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 71
Study 8394749 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of rhinovirus
Number of subjects: 71
Study 8394749 — intervention group
Group type: COMPARATOR
Intervention: Other viruses (respiratory syncytial virus, parainfluenza virus, influenza virus)
Number of subjects: 71
Study 3118579 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus glibenclamide
Number of subjects: 79
Study 3118579 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 79
Study 3118579 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide withdrawal
Number of subjects: 79
Study 3118579 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 79
Study 3118579 — intervention group
Group type: COMPARATOR
Intervention: Short-term effects
Number of subjects: 79
Study 2256787 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime continued treatment
Number of subjects: 101
Study 2256787 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin replacement treatment
Number of subjects: 101
Study 2256787 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone administration
Number of subjects: 101
Study 2256787 — intervention group
Group type: EXPERIMENTAL
Intervention: IV treatment cessation by the 10th day
Number of subjects: 101
Study 2256787 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment with IIIrd generation cephalosporin
Number of subjects: 101
Study 2256787 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitution by ampicillin or amoxicillin
Number of subjects: 101
Study 1137256 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted digoxin therapy
Number of subjects: 51
Study 1137256 — intervention group
Group type: COMPARATOR
Intervention: Physician-regulated digoxin therapy
Number of subjects: 51
Study 30741577 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating (SL) brackets
Number of subjects: 25
Study 30741577 — intervention group
Group type: COMPARATOR
Intervention: Conventional (CV) brackets
Number of subjects: 25
Study 28244929 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoelace ACL Simulation Guide
Number of subjects: 10
Study 28244929 — intervention group
Group type: COMPARATOR
Intervention: Instructional video only
Number of subjects: 10
Study 25395071 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 30
Study 25395071 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 30
Study 25395071 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 24925984 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400 mg
Number of subjects: 662
Study 24925984 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral aripiprazole (10-30 mg/day)
Number of subjects: 662
Study 24925984 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole once-monthly 50 mg
Number of subjects: 662
Study 22552758 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron (15 mg twice per day)
Number of subjects: 36
Study 22552758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19912088 — intervention group
Group type: EXPERIMENTAL
Intervention: Fagerström Test for Nicotine Dependence (FTND)
Number of subjects: 201
Study 19912088 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported smoking status
Number of subjects: 201
Study 19912088 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary cotinine concentrations
Number of subjects: 201
Study 19912088 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of cigarettes smoked
Number of subjects: 201
Study 17878429 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation (group N)
Number of subjects: 53
Study 17878429 — intervention group
Group type: COMPARATOR
Intervention: Manual operation (group M)
Number of subjects: 53
Study 15523183 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro (LP)
Number of subjects: 27
Study 15523183 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin (RH)
Number of subjects: 27
Study 12490271 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopeptin 1.5 mg
Number of subjects: 31
Study 12490271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 12490271 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary ultrasound (sub-group of patients)
Number of subjects: 31
Study 9620513 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.4 mg/mL
Number of subjects: 91
Study 9620513 — intervention group
Group type: COMPARATOR
Intervention: Control (without ketamine)
Number of subjects: 91
Study 7542134 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (Proscar) therapy for BPH
Number of subjects: 30
Study 2377755 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide scintigraphy
Number of subjects: 31
Study 2377755 — intervention group
Group type: COMPARATOR
Intervention: Barium meal X-ray
Number of subjects: 31
Study 2377755 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of barium X-ray and scintigraphy
Number of subjects: 31
Study 205811 — intervention group
Group type: EXPERIMENTAL
Intervention: 1300 international units of vitamin D2/d
Number of subjects: 86
Study 205811 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 international units of vitamin D2/d
Number of subjects: 86
Study 205811 — intervention group
Group type: EXPERIMENTAL
Intervention: 1300 international units of vitamin D3/d
Number of subjects: 86
Study 205811 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 international units of vitamin D3/d
Number of subjects: 86
Study 31660918 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Sexuality Education (CSE) intervention
Number of subjects: 1096
Study 31660918 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1096
Study 28522433 — intervention group
Group type: EXPERIMENTAL
Intervention: Educative website on suicide prevention
Number of subjects: 161
Study 28522433 — intervention group
Group type: COMPARATOR
Intervention: Unrelated website (control group)
Number of subjects: 161
Study 25528143 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined users (alcohol and energy drinks in the same beverage or on the same occasion)
Number of subjects: 439
Study 25528143 — intervention group
Group type: COMPARATOR
Intervention: Separate users (alcohol and energy drinks on separate occasions)
Number of subjects: 439
Study 25528143 — intervention group
Group type: COMPARATOR
Intervention: Non-Users (those who drank alcohol, but not energy drinks)
Number of subjects: 439
Study 25528143 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined users
Number of subjects: 439
Study 23085971 — intervention group
Group type: EXPERIMENTAL
Intervention: 20,000 kg load-volume
Number of subjects: 8